In November 2017, the FDA approved the digital pill Abilify MyCite to treat schizophrenia, depression, and bipolar disorder(1); a one-month supply costs $1,500, well out of range of affordability for many suffering from schizophrenia(2). The pill includes a digital sensor that reacts with stomach acid when taken, sending a signal to a patch worn by the patient that then sends a signal to a smartphone app notifying up to five people that the pill was taken. At the time of approval, concerns arose over how this new capability opened the door to various abuses, though there was little discussion of the worrying possibility of how such technology could be used by repressive governments. The cost is nearly 30 times the cost of the generic pill for a 30-day supply. Schizophrenia affects approximately 1 percent of the population, yet a meta-analysis of 31 studies involving 51,925 people who were homeless found …